Vitamin B 6 Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Vitamin B 6 Deficiency. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Vitamin B 6 Deficiency receives a directional score of 66/100, combining unmet need (78/100), competitive intensity (62/100) and market attractiveness (71/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A nutritional condition produced by a deficiency of VITAMIN B 6 in the diet, characterized by dermatitis, glossitis, cheilosis, and stomatitis. Marked deficiency causes irritability, weakness, depression, dizziness, peripheral neuropathy, and seizures. In infants and children typical manifestations are diarrhea, anemia, and seizures. Deficiency can be caused by certain medications, such as isoniazid.

The reproducible record is Patsnap disease ID b6d9b6220d004f50bf3fd6fa85b05466 and MeSH identifier D026681. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

• Among 134 480 participants in the Shanghai Men’s Health Study (conducted from 2002–2014) and the Shanghai WHS (conducted from 1997–2014), the aHR for CVD mortality in the highest versus lowest quintiles of dietary vitamin B6 intake was 0.73 (95% CI, 0.63–0.85) in males and 0.80 (95% CI, 0.70–0.92) in females.39 • The US IMPACT Food Policy Model, a computer simulation model, projected that a national pol­ icy combining a 30% fruit and vegetable subsidy targeted to low-income Supplemental Nutrition Assistance Program recipients and a population- wide 10% price reduction in fruits and vegetables in the remaining population could prevent ≈230 000 deaths by 2030 and reduce the socioeconomic dis­ parity in CVD mortality by 6%.40 Awareness, Treatment, and Control • According to data from NHANES among 35 416 participants in 2013 to 2016, the prevalence of controlled BP (SBP <130 mm Hg and DBP <80 mm Hg) among participants with hypertension was 30% in females and 22% in males; the prevalence of controlled diabetes (HbA1c <6.5%) among par­ ticipants with diabetes was 30% in females and 20% in males; and the prevalence of TC <240 mg/ dL among participants with dyslipidemia was 51% in females and 63% in males.7 • Among 5246 individuals from rural China partici­ pating in the MIND-China study, the prevalence of CVD was 35%. CVD was defined as the presence of ischemic HD, HF, AF, or stroke from a combi­ nation of self-reported medical history, ECG, and a neurological examination. Among those with prevalent CVD, the most commonly used therapies were calcium channel blockers (17.7%), tra

Review source

Epidemiology evidence 2: Prevalence of Vitamin A Deficiency in Children Aged 6 to 17 Years — Western and Central Rural Areas, China, 2012–2021 Prevalence of Vitamin A Deficiency in Children Aged 6 to 17 Years— Western and Central Rural Areas, China, 2012–2021

Prevalence of Vitamin A Deficiency in Children Aged 6 to 17 Years — Western and Central Rural Areas, China, 2012–2021 Prevalence of Vitamin A Deficiency in Children Aged 6 to 17 Years — Western and Central Rural Areas, China, 2012–2021 Peipei Xu1; Juan Xu1; Wei Cao1; Titi Yang1; Qian Gan1; Hongliang Wang1; Ruihe Luo1; Hui Pan1; Qian Zhang1,# Summary What is already known about this topic? Vitamin A deficiency (VAD) is a leading global nutritional concern, ranking among the top four major nutritional deficiencies worldwide. The prevalence of VAD is unevenly distributed across various regions, both within China and globally. What is added by this report? The report adds valuable insights into the vitamin A nutritional status of rural students aged 6–17 years who participated in the Nutrition Improvement Programme for Rural Compulsory Education Students (NIPRCES). Over the decade from 2012 to 2021, there was a modest improvement in vitamin A status. The prevalence of VAD and sub-clinical VAD (SVAD) declined as the students aged. Throughout the majority of the survey years, the incidence of VAD was higher among males and western regions compared to females and central regions, respectively. What are the implications for public health practice? A comprehensive approach, incorporating dietary diversification, nutrition education, and food fortification, should be implemented to prevent VAD and SVAD especially in males, younger children and children in western areas. Vitamin A is critical for the growth, development, visual function, and immune response of children, as along with

Review source

Epidemiology evidence 3: China CDC Weekly Reports (Vol. 7 No. 23 Jun. 6, 2025) Prevalence of Micronutrient Deficiencies in Children andAdolescents Aged 3–17 Years — 14 PLADs,China, 2019–2021

comparisons revealed statistically significant differences (all P<0.05). Among children aged 6–17 years in urban areas and children aged 9–17 years in rural areas, girls exhibited significantly higher VDD prevalence than boys (all P<0.05). No significant urban-rural differences in VDD prevalence were observed across any age group regardless of gender (all P>0.05) (Table 2). The overall VDI prevalence was 41.2% among children aged 3–17 years in China. VDI prevalence was higher in children aged 9–11 years (44.1%) and 12–14 years (44.4%) compared to those aged 3–5 years (26.8%), 6–8 years (39.8%), and 15–17 years (40.9%). No significant differences were found between the 9–11 and 12–14 years age groups (P>0.05), or between the 6–8 and 15–17 years age groups (P>0.05); however, all other age group comparisons revealed statistically significant differences (all P<0.05). In rural settings, girls demonstrated significantly higher VDI prevalence than boys (P<0.05) in the 6–8 years age group, while showing significantly lower VDI prevalence than boys (P<0.05) in the 12–14 years age group. VDI prevalence was significantly higher in urban areas than in rural areas for girls aged 12–17 years (all P>0.05) (Table 2). Iron deficiency affected 10.9% of children aged 3–17 years in China, with significantly higher prevalence in adolescents aged 12–17 years compared to children aged 3–11 years (all P<0.05). Among adolescents aged 12–17 years, girls demonstrated significantly higher iron deficiency rates than boys in both urban and rural settings (all P<0.05). Among children aged 3–5 years, boy

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Vitamin B 6 Deficiency, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Vitamin B 6 Deficiency thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 7 registered studies.

• ChiCTR2600129998 — Two Clinical Cases of Pyridoxal 5′-Phosphate-Binding Protein (PLPBP) Deficiency; Not yet recruiting; Not Applicable; sponsor Foshan Maternity and Child Health Care Hospital; enrollment 2.
• NCT05649293 — Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder; Unknown status; Not Applicable; sponsor Assiut University; enrollment 94.
• NCT03447275 — The Vitamin B Status in Type 2 Diabetes (VITA) Study (VITA); Completed; Not Applicable; sponsor Universität des Saarlandes, syneed medidata GmbH, Merck KGaA; enrollment 174.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate C5 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Vitamin B 6 Deficiency merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Vitamin B 6 Deficiency is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.